Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Wayne Paulekas

Internal Medicine Wethersfield, CT Medical Doctor

NPI 1730166422 CMS profile 215034

30 Jordan Ln, Wethersfield, CT 06109

Open in the dashboard

General payments

$3,896

220 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Wayne Paulekas of Wethersfield, CT is reported in the CMS Open Payments database as having received $3,896 across 220 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 87th percentile of Internal Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $967 45
2024 General $298 13
2023 General $192 11
2022 General $418 21
2021 General $456 24
2020 General $424 27
2019 General $1,141 79

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Wayne Paulekas
  • Internal Medicine median
  • Middle half of Internal Medicine
  • National median

In program year 2025, general payments to Wayne Paulekas were reported at $967. Among 52,115 Internal Medicine profiles paid that year, the median was $156 and the middle half received between $47 and $551.

Show as a table
Year Wayne Paulekas Internal Medicine median Middle half National median
2019 $1,141 $159 $48–$570 $163
2020 $424 $119 $33–$402 $114
2021 $456 $135 $37–$521 $132
2022 $418 $141 $42–$496 $149
2023 $192 $149 $45–$519 $160
2024 $298 $154 $47–$537 $164
2025 $967 $156 $47–$551 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Pfizer Inc. $473 31 payments
  2. AstraZeneca Pharmaceuticals LP $458 24 payments
  3. AbbVie, Inc. $444 24 payments
  4. GlaxoSmithKline, LLC. $276 17 payments
  5. Astellas Pharma US Inc $273 14 payments
  6. Janssen Pharmaceuticals, Inc $239 16 payments
  7. Boehringer Ingelheim Pharmaceuticals, Inc. $176 9 payments
  8. Novo Nordisk Inc $151 8 payments
  9. Allergan Inc. $141 13 payments
  10. Takeda Pharmaceuticals U.S.A., Inc. $92 4 payments
  11. Other $1,172 60 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $3,871 217 payments
  2. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $15 1 payment
  3. Education $10 2 payments
Products named General payments · program years 2019–2025
  1. BREZTRI $244 11 payments
  2. TRELEGY ELLIPTA $243 15 payments
  3. XARELTO $239 16 payments
  4. UBRELVY $227 10 payments
  5. MYRBETRIQ $219 12 payments
  6. VRAYLAR $199 13 payments
  7. COLOGUARD $180 12 payments
  8. ELIQUIS $161 10 payments
  9. INVOKANA $126 8 payments
  10. FARXIGA $111 7 payments
  11. Other $2,872 166 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 165 drugs

Part D claims

10,405

Median for Internal Medicine: 777

Drug cost

$950,436

Median for Internal Medicine: $73,373

Branded share of claims

20.9%

Median for Internal Medicine: 19.3%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Eliquis Apixaban Brand 342 $167,671
Jardiance Empagliflozin Brand 99 $114,065
Ozempic Semaglutide Brand 42 $79,937
Farxiga Dapagliflozin Propanediol Brand 88 $79,636
Xarelto Rivaroxaban Brand 122 $77,846
Januvia Sitagliptin Phosphate Brand 61 $54,195
Myrbetriq Mirabegron Brand 69 $39,965
Mounjaro Tirzepatide Brand 31 $37,429
Epidiolex Cannabidiol (Cbd) Brand 19 $35,729
Gemtesa Vibegron Brand 45 $22,259

The 10 drugs with the highest cost, of 165 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 104,182 Part D prescribers listed as Internal Medicine; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 34 billing codes

Paid by Medicare

$106,538

Of which drugs: $4,570

Medicare patients

285

Average age 79

Services billed

1,691

145 women, 140 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 50%
Ischemic heart disease 32%
Depression 31%
Atrial fibrillation 27%
Diabetes 24%
Chronic kidney disease 23%
Heart failure 21%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Vaccine for influenza for injection into muscle 90653 Office 41 41 $3,355

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 9 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
Veozah
  • Astellas Pharma US Inc $54
$54 — —
TRINTELLIX
  • Takeda Pharmaceuticals U.S.A., Inc. $44
$44 — —
JARDIANCE
  • Boehringer Ingelheim Pharmaceuticals, Inc. $41
$41 99 —
FARXIGA
  • AstraZeneca Pharmaceuticals LP $39
$39 88 —
GEMTESA
  • Sumitomo Pharma America, Inc. $25
$25 45 —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 9 in the dashboard with a free account

Records

220 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Internal Medicine in Connecticut

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record